Breadth And Depth Of Bristol-Myers Squibb’s Immuno-Oncology Clinical Development Program To Be Showcased At 2016 ASCO Annual Meeting

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today 36 presentations, including seven oral presentations and eight poster discussions, highlighting data from studies evaluating Opdivo® (nivolumab), Yervoy® (ipilimumab), Empliciti™ (elotuzumab) and Sprycel® (dasatinib), across 13 types of cancers, will be featured at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 3-7. The data presented at this meeting builds on the Company’s understanding of the clinical profile of these agents – as monotherapy or in combination – and reinforce its commitment to addressing significant unmet patient needs in a wide range of solid tumors and blood cancers.